Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

A trend towards a higher density of PD-L1+ cells within baseline tumor biopsies was noted in patients with DLBCL who went on to respond to odronextamab versus non-responders, and an overall trend towards an increase in PD-L1+ cells from baseline to Week 5 was noted in patients with both DLBCL and FL ( online supplemental figure 2 ).

also in 3,038 other papers

There was a statistically significant increase (p=0.019) in Tregs in responders versus non-responders, in addition to a numerical trend for increased overall baseline CD3 T cells and CD8 T cells in responders.

also in 728 other papers